ProPhase Labs faces a critical inflection point as it struggles to transition from its post-pandemic diagnostic revenue base, evidenced by a persistent revenue decline and recurring net losses.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 19, 2026 | -$0.22 vs — | $1M vs — |
Q3 2026 Jun 30, 2026 | -$0.43 vs — | $478,000 vs — |
Q3 2026 Jun 24, 2026 | -$0.87+27.5% vs -$1.20 | $784,000-91.9% vs $10M |
Q3 2026 Jun 22, 2026 | -$0.87+27.5% vs -$1.20 | $784,000-91.9% vs $10M |
ProPhase Labs (NASDAQ: PRPH - Get Free Report) and Aurora Cannabis (NASDAQ: ACB - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability. Institutional and Insider Ownership 9.4% of ProPhase
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and ProPhase Labs (NASDAQ: PRPH - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends. Earnings and Valuation This table compares Takeda Pharmaceutical
Benchmark PRPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ProPhase Labs, Inc. (PRPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $72.88K | -0.00 | -35.82% | -717.43% | -1358.66% | — | |
| $10.70 | $729.64M | -1.99 | -1.89% | -14.24% | -20.13% | — | |
| $4.82 | $2.5B | 216.14 | 40.34% | 0.45% | 3.52% | — | |
| $1.15 | $13.2M | -0.41 | -7.37% | -106.58% | -78.78% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $23.74 | $674.23M | -7.22 | 13.83% | -27.53% | -8.8% | — |
ProPhase Labs, Inc. (PRPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ProPhase Labs, Inc. (PRPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Feb 13, 2026·SEC
Feb 13, 2026·SEC
Get notified when PRPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ProPhase Labs, Inc. (PRPH) stock FAQ — growth, dividends, profitability & financials explained
ProPhase Labs, Inc. (PRPH) reported $3.2M in revenue over the trailing twelve months. Revenue was $4.3M in fiscal year 2025. That is 443% more than the $0.8M of fiscal year 1996.
ProPhase Labs, Inc. (PRPH) revenue fell by 5.5% over the trailing twelve months, compared with the twelve months before.
No. ProPhase Labs, Inc. (PRPH) reported a net loss of $22.6M over the trailing twelve months.
ProPhase Labs, Inc. (PRPH) had a return on equity (ROE) of -1358.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
ProPhase Labs, Inc. (PRPH) had negative free cash flow of $30.7M over the trailing twelve months.
